688 Transcriptome analyses in patients with myeloid malignances treated with the IRAK4 inhibitor emavusertib

• Daniel J DeAngelo,
• Chia-Cheng Li,
• Amit Verma,
• Mariano Severgnini,
• David Nickle,
• Guillermo Garcia-Manero,
• Uwe Platzbecker,
• Reinhard von Roemeling,
• Klaus H Metzeler,
• Eric S Winer,
• Gaurav S Choudhary,
• Wanying Zhao,
• Maureen Lane,
• Alyssa Masciarelli,
• Dora Ferrari,
• Cole Gallagher,
• Samantha Carlisle

Affiliations

Daniel J DeAngelo

2 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

Chia-Cheng Li

3 Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA

Amit Verma

1Anesthesiology institute, Cleveland clinic abu dhabi, Abu Dhabi, United Arab Emirates

Mariano Severgnini

Center for Immuno-Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

David Nickle

6Gossamer Bio, Inc., San Diego, CA, USA

Guillermo Garcia-Manero

3Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Uwe Platzbecker

2 Medizinische Klinik und Poliklinik I, Universitatsklinikum Carl Gustav Carus, Dresden, Germany

Reinhard von Roemeling

2Curis Inc., Lexington, MA, USA

Klaus H Metzeler

1University Hospital Leipzig, Leipzig, Germany

Eric S Winer

2Dana-Farber Cancer Institute, Boston, MA, USA

Gaurav S Choudhary

4Curis Inc, Lexington, MA, USA

Wanying Zhao

4Curis Inc, Lexington, MA, USA

Maureen Lane

4Curis Inc, Lexington, MA, USA

Alyssa Masciarelli

4Curis Inc, Lexington, MA, USA

Dora Ferrari

4Curis Inc, Lexington, MA, USA

Cole Gallagher

4Curis Inc, Lexington, MA, USA

Samantha Carlisle

5Monoceros Biosystems, San Diego, CA, USA